Pharmafile Logo
Pharmafocus logo
Advanced Search

lung cancer

Showing 15 posts of 203 posts found.

Roche says combination therapy with its Avastin and Tarceva gets European backing for lung cancer treatment

June 8, 2016
Research and Development, Sales and Marketing European Commission, NSCL, RegulationC, Roche, Tarceva, avastin, drug trial, lung cancer

Cancer drugmaker Roche (SIX: ROG) on Wednesday said the European Commission has approved its Avastin (bevacizumab) in combination with Tarceva …

News
novartis_outside_1

Novartis says Phase II data for rare lung cancer showed overall response rate of 63%

June 7, 2016
Manufacturing and Production, Research and Development, Sales and Marketing ASCO, Novartis, Tafinlar, drug trial, lung cancer, mekinist

Swiss drugmaker Novartis (VTX: NOVN) said combination mid-stage trials for the drug to treat a rare and aggressive form of …

News
abbvie_0

AbbVie says Stemcentrx’ lung cancer drug shows some benefits in early trials

June 6, 2016
Manufacturing and Production, Research and Development, Sales and Marketing ASCO, AbbVie, Stemcentrx, drug trial, lung cancer, rova-t

US drug firm AbbVie (NYSE: ABBV) said its early-stage trials for its drug to treat an aggressive form of lung …

News
abbvie_0

AbbVie says Stemcentrx’ stem cell drug shows some benefits in early trials

June 6, 2016
Manufacturing and Production, Research and Development, Sales and Marketing ASCO, AbbVie, Stemcentrx, drug trial, lung cancer, rova-t

US drug firm AbbVie (NYSE: ABBV) said its early-stage trials for its drug to treat an aggressive form of lung …

News

Trial data shows promise for Lilly/MSD combo regimen in lung cancer

June 6, 2016
Research and Development, Sales and Marketing MSD, Merck, collaboration, immuno-oncology, lilly, lung cancer, non-small cell, parternship

Eli Lilly (NYSE: LLY) has presented data at the American Society of Clinical Oncology (ASCO) annual congress showcasing its collaborations …

News
eli_lilly_logo

Nice does not recommend Eli Lilly’s lung cancer drug in draft guidance

May 26, 2016
Research and Development, Sales and Marketing Cancer Drugs Fund, Eli Lilly, NICE, lung cancer

The National Institute of Care and Excellence (Nice) did not recommend US drugmaker Eli Lilly’s (NYSE: LLY) Portrazza to treat …

News
novartis_side_building

Nice backs Novartis’ lung cancer drug

May 20, 2016
NHS, NICE, Novartis, ceritinib, lung cancer, recommendation, regulation

The National Institute for Health and Care Excellence (Nice) has recommended Novartis’ (VTX: NOVN) Ceritinib (zykadia) as a treatment for …

News
bmslogo

BMS says Phase III trials for Opdivo show improved overall survival in lung cancer

May 19, 2016
Research and Development Bristol-Myers Squibb, drug trial, lung cancer, opdivo

Bristol-Myers Squibb (NYSE:BMY) said late-stage trials for its immuno-therapy Opdivo (nivolumab) showed improved overall survival in lung cancer at the …

News
birdlr

Boehringer Ingelheim’s Giotrif significantly lowers lung cancer progression in Phase II trials

April 13, 2016
Research and Development AstraZeneca, Boehringer Ingelheim, Iressa, giotrif, lung cancer

German drugmaker Boehringer Ingelheim on Wednesday said a mid-stage study has shown its cancer drug Giotrif (afatinib) reduced the risk …

News
cancerstudy

FDA staff raises doubts on efficacy, safety of Clovis’ trial drug for lung cancer, shares plunge

April 11, 2016
AstraZeneca, Clovis Oncology, US FDA, drug trial, lung cancer, regulation, rociletinib

Shares in Clovis Oncology Inc (Nasdaq: CLVS) plunged to close down nearly 18% after the US regulators expressed doubts if …

News
roche__tree

Roche’s cancer immunotherapy for lung cancer gets US FDA priority review

April 11, 2016
Business Services, Research and Development, Sales and Marketing Roche, US FDA, atezolizumab, lung cancer

Swiss drug firm Roche (SIX: ROG) on Monday said the US Food and Drug Administration (FDA) has accepted its Biologics …

News
bi_centre_03_2

Boehringer Ingelheim’s Giotrif gets Europan regulatory backing in another lung cancer indication

April 7, 2016
Business Services, Research and Development, Sales and Marketing Boehringer Ingelheim, European Commission, giotrif, lung cancer

German drugmaker Boehringer Ingelheim on Thursday said European regulators have granted marketing rights for its non-small cell lung cancer (NSCLC) …

News
takeda_research_centre

Japanese approval for AZ lung cancer drug

March 29, 2016
Manufacturing and Production, Sales and Marketing AstraZeneca, Tagrisso, lung cancer

AstraZeneca’s Tagrisso (osimertinib) has been approved in Japan for the treatment of a specific form of clung cancer. Japanese regulator, …

News
Keytruda image

MSD’s Keytruda impresses in lung cancer chemotherapy trial

December 21, 2015
Manufacturing and Production, Research and Development MSD, PD-L1, docetaxel, keytruda, lung cancer, non small cell lung cancer, non-small cell lung cancer, pd-1, pembrolizumab

MSD’s Keytruda significantly improved overall survival (OS) compared to chemotherapy in people with lung cancer and PD-L1 expression, a trial …

News
NHS sign

NICE rejects BMS cancer drug in draft guidance

December 16, 2015
Research and Development, Sales and Marketing BMS, Bristol-Myers Squibb, NHS, NICE, lung cancer, nivolumab, non small cell lung cancer, non-small cell lung cancer, opdivo

In draft guidance, NICE has chosen not to recommend Bristol-Myers Squibb’s Opdivo for the treatment of locally advanced or metastatic …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025